Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2 · Recruiting · Enrollment 200

NCT07114419

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Efsubaglutide 20 mg Quaque Week (QW)n/rn/rn/rn/r
Efsubaglutide 40 mg QWn/rn/rn/rn/r
Efsubaglutide Alfa 40 mg Q2Wn/rn/rn/rn/r
Efsubaglutide Alfa 80 mg QWn/rn/rn/rn/r
Efsubaglutide Alfa 80 mg Q4Wn/rn/rn/rn/r

Not shown

  • Efsubaglutide 20 mg Quaque Week (QW): endpoint not reported
  • Efsubaglutide 40 mg QW: endpoint not reported
  • Efsubaglutide Alfa 40 mg Q2W: endpoint not reported
  • Efsubaglutide Alfa 80 mg QW: endpoint not reported
  • Efsubaglutide Alfa 80 mg Q4W: endpoint not reported